Business
Allergy Therapeutics (AGY): House dust mite vac...
Allergy Therapeutics (AGY): House dust mite vac....
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress21-May-2019 / 07:15 GMT/BST\nHardman & Co: House dust mite vaccine - clinical progress\n\nAGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a 'named-patients' (NP) basis only. The aim of ongoing trials is to move the platform to full registration under the new regulatory framework. Following the success of 'Acarovac Plus' in NP, the 'Acarovac MPL' vaccine for house dust mite allergy is in clinical development to provide a registered vaccine. Results from the Phase I trial of Acarovac MPL were positive, demonstrating safety and tolerability.\n\nPlease click here for the full report:\n\nhttps://www.hardmanandco.com/research/corporate-research/house-dust-mite-vaccine-clinical-progress/\n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave+44 20 7194 7622\n [email protected]@[email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the ru...